HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GSK2656157

a deazaadenine; inhibits PERK protein kinase

Networked: 15 relevant articles (3 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Adenine: 2120
        GSK2656157: 15
    - Indoles: 200
      - GSK2656157: 15

Experts

1.	Gupta, Rajaneesh: 2 articles (01/2020 - 01/2017)
2.	Sen, Nilkantha: 2 articles (01/2020 - 01/2017)
3.	Sen, Tanusree: 2 articles (01/2020 - 01/2017)
4.	Jung, Hye Seung: 2 articles (01/2019 - 01/2018)
5.	Kim, Mi Na: 2 articles (01/2019 - 01/2018)
6.	Kim, Min Joo: 2 articles (01/2019 - 01/2018)
7.	Min, Se Hee: 2 articles (01/2019 - 01/2018)
8.	Park, Kyong Soo: 2 articles (01/2019 - 01/2018)
9.	Abakumova, Olena S: 1 article (01/2020)
10.	Feng, Yong: 1 article (01/2020)

Related Diseases

1.	Body Weight (Weight, Body) 01/01/2018 - "In both wild-type and insulin-deficient Atg7-knockout mice, 8 weeks of GSK2656157 treatment enhanced GSIS and improved hyperglycemia without affecting body weight. " 01/01/2019 - "Several doses (6-16 mg/kg/day) of GSK2656157 and glimepiride were administrated to the mice for 8 weeks, and metabolic phenotypes were evaluated such as body weight, blood glucose levels, insulin secretion and sensitivity, and then changes in the pancreas were measured. "
2.	Hyperglycemia 01/01/2018 - "In both wild-type and insulin-deficient Atg7-knockout mice, 8 weeks of GSK2656157 treatment enhanced GSIS and improved hyperglycemia without affecting body weight. "
3.	Hypoxia (Hypoxemia) 11/04/2017 - "Moreover, the down-regulated expression of adiponectin induced by hypoxia was relieved once the PERK and IRE1 signaling pathways were suppressed by the inhibitors GSK2656157 and 4μ8C, respectively. "
4.	Neuroinflammatory Diseases 01/01/2020 - "Blocking PERK phosphorylation using GSK2656157 (or PERK knockdown) the whole cascade of neuroinflammation was attenuated and improved cognitive function after TBI."
5.	Infections 11/12/2023 - "GSK2656157, a PERK Inhibitor, Alleviates Pyroptosis of Macrophages Induced by Mycobacterium Bacillus Calmette-Guerin Infection." 11/12/2023 - "In this study, Bacillus Calmette-Guerin (BCG) infection resulted in high expression of pro-caspase-1, caspase-1 p20, GSDMD-N, and p-PERK in the THP-1 macrophage, being downregulated with the pre-treatment of GSK2656157, a PERK inhibitor. " 12/20/2022 - "We reported that the combination of sub-cutaneous (SC) and intraperitoneal (IP) administration of PERK pathway inhibitors (GSK2656157 and ISRIB) cures local as well as systemic GAS infection in a NF murine model, by reducing asparagine release at the infection site. " 11/12/2023 - "In addition, GSK2656157 inhibited the secretion of IL-1β and IL-18, cell content release, and cell membrane rupture, as well as the decline in cell viability induced by BCG infection. "

Related Drugs and Biologics

1.	Adiponectin
2.	Insulin (Novolin)
3.	Caspase 1 (ICE Protease)
4.	Small Interfering RNA (siRNA)
5.	Interleukin-18 (Interleukin 18)
6.	Proteins (Proteins, Gene)
7.	Oxygen (Dioxygen)
8.	Glucose (Dextrose)
9.	Blood Glucose (Blood Sugar)
10.	Asparagine

Related Therapies and Procedures

1.	Therapeutics